Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
20.91%
operating margin TTM
23.38%
revenue TTM
1.93 Billion
revenue per share TTM
19.18$
valuation ratios | |
|---|---|
| pe ratio | 22.48 |
| peg ratio | 0.22 |
| price to book ratio | 4.33 |
| price to sales ratio | 4.72 |
| enterprise value multiple | 17.28 |
| price fair value | 4.33 |
profitability ratios | |
|---|---|
| gross profit margin | 97.97% |
| operating profit margin | 23.38% |
| pretax profit margin | 27.87% |
| net profit margin | 20.91% |
| return on assets | 13.16% |
| return on equity | 21.13% |
| return on capital employed | 17.59% |
liquidity ratios | |
|---|---|
| current ratio | 1.87 |
| quick ratio | 1.75 |
| cash ratio | 0.38 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 554.42 |
| operating cycle | 650.38 |
| days of payables outstanding | 755.54 |
| cash conversion cycle | -105.16 |
| receivables turnover | 3.80 |
| payables turnover | 0.48 |
| inventory turnover | 0.66 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.07 |
| debt equity ratio | 0.11 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.10 |
| interest coverage | 272.03 |
| cash flow to debt ratio | 2.24 |
cash flow ratios | |
|---|---|
| free cash flow per share | 8.62 |
| cash per share | 3.86 |
| operating cash flow per share | 8.89 |
| free cash flow operating cash flow ratio | 0.97 |
| cash flow coverage ratios | 2.24 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 32.42 |
Frequently Asked Questions
When was the last time Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reported earnings?
Neurocrine Biosciences, Inc. (NBIX) published its most recent earnings results on 31-07-2026.
What is Neurocrine Biosciences, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)'s trailing twelve months ROE is 21.13%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Neurocrine Biosciences, Inc. (NBIX) currently has a ROA of 13.16%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did NBIX's net profit margin stand at?
NBIX reported a profit margin of 20.91% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is NBIX's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.87 in the most recent quarter. The quick ratio stood at 1.75, with a Debt/Eq ratio of 0.11.